PMPRB Framework modernization is underway with significant changes pending to both the Patented Medicine’s Regulations and PMPRB Pricing Guidelines. Gather insights on:
Discover what regulatory changes can mean to your market access strategy.
Governments, payers and healthcare’s other stakeholders increasingly look to incorporate data to support decision-making. Explore innovation in Real-World Evidence to improve the value, efficacy and impact of medicines. Take away strategies to:
Prove and improve the value, efficacy and impact of your medicines with RWE.
The Regulatory Review of Drugs and Devices (R2D2) initiative is underway. Review the objectives of this initiative to improve access to therapeutic products Stay up-to-date on:
Analyze the R2D2 initiative to bolster access to treatment
With pCODR review and possible re-review, patients can wait 2 to 4 years for access to innovative cancer treatments. Advance your submission strategy to include broader stakeholder insights. Source Intelligence to:
Review the effect of all stakeholder submissions to better strategize your market access strategy
Reconciling the urgency of patient need with a thorough HTA process is a growing a challenge. Explore what patients expect from you to improve patient outcomes. Gain insights to:
Ensure the patients are at the centre of your strategic planning.
The private payer landscape is undergoing significant changes that will impact patient access and how medications are reimbursed. Strengthen your market access strategy with insights into emerging trends in the private payer landscape. Source critical information to:
Integrate the employer’s outlook into your market access strategies.
Driving Value Out of Upstream Data
In a highly regulated pricing market pharmaceutical companies look to incorporate differential pricing domestically to increase patient access. Review how to approach Canadian “differential pricing” to increase patient access. Gain insights to:
Join us for a timely and stimulating discussion that will inform your pricing strategy development for future launch products.
Real-world evidence can be a challenge due to the complexity of the data. Learn from Sanofi’s experience to strategize your data management. Gain practical tips to:
Gain practical insights on the challenges of RWE from Sanofi’s experience.
Collaboration is key to stimulate the life sciences sector in our country. Meet shared objectives with public partners to advance access and affordability.
ODANO is a new Ontarian drug access navigator to facilitate cancer drug coverage. Analyze the impact of drug access navigators on patients to increase speed of reimbursement. Gain insights on:
Explore what drug access navigators can do to increase the speed of reimbursement.
The next wave of biosimilars is about to enter the Canadian market and present unique issues not part of the current landscape. Learn about the considerations associated with institutionally-based products such as oncology monoclonal antibodies, including:
Assess the considerations for Oncology biosimilars.
Demands on more value for healthcare dollars are driving policy and
systems-wide changes. Ensure you play a role in enabling patient
access and quality of care. Sources strategies to:
Strategize and plan accordingly to get the attention of market access
Regional health authorities are working to improve alignment with public drug plans and utilize the best available evidence when reviewing hospital only drugs. Analyze the NFC and the hospital formulary review process in Alberta to improve your market access strategy. Gain insights to:
Evaluate the evolution of decision-making at the regional level and its effects on your organization.
CDR guideline are likely to change and major lab diagnostic testing companies and patient support programs are pro-acting for this eventuality. Adapt to changing CDR guidelines and Improve your submissions with companion diagnostic tests. Source intelligence to:
Strengthen your new submission with relevant companion diagnostic tests.
With long negotiations and shrinking budgets, patients are likely to wait longer to get reimbursed. Stay in tune with payer priorities to ensure that your patients are quickly reimbursed. Develop your action plan to:
Adapt your value proposition to ensure the coverage of your treatments.
The pCPA changed notably in the past few years and its approach to negotiation has evolved. Reassess your expectation and improve your submissions. Source Intelligence to:
Revise changes at pCPA to enhance your submission process.
The trends occurring in the public and private plan designs are essential to developing your market access strategy. Leverage data insights within the patient support program environment to move from a reimbursement focus to an evidence generation focus. Discover insights to:
Analyze how the changing reimbursement landscape is impacting market access to optimize your company’s access strategies.
Since the 2014 general election, the Quebec Government has shown the desire to proceed with major cut backs in the healthcare system. Wide-ranging reforms, aimed at conclusively fixing Quebec’s health system, are impacting service providers, manufacturers, healthcare professionals, and patients. Explore how your organization can position itself in this turbulent time. Master the success factors to:
List your projects in the government's vision.
CADTH CDR made changes to improve transparency and HTA timelines. Explore what these changes can do to streamline your submissions. Source intelligence on:
Align with new CDR guidelines to advance your approval processes.
Collaboration is a crucial aspect of R&D and early stage of new product launches. Ensure a successful launch for your new products and advance access to treatments. Gain insights to:
Bolster your product development and make innovative health treatment available on the market.
National Pharmacare continues to be the focus of research studies and political initiatives. Analyze the issues and offer a critical assessment of the latest research and the prospects for universal coverage of prescription medicines in Canada. Gain insights on:
Review the latest research and the prospects for universal coverage of prescription medicines in Canada.
Small markets can impede the development of orphan drugs, but collaboration can alleviate some restraints. Build partnerships to develop your new products and secure revenue opportunities. Build a roadmap to:
Work with your stakeholders to increase patient access to treatments.
Although speciality drugs represent 5% of prescriptions, they represent 20–25% of the benefits paid. Review your pricing strategy to reduce delays in listing.
Plan your negotiation strategy to streamline listing of your high priced drugs.
Private sponsors need a clear value-proposition to enhance their benefit plans. Clarify your value proposition to ensure employees access to the best treatments. Gain practical insights to:
Include sponsor insights in your value proposition to increase patient access to treatments.
The Pan-Canadian Competitive Value Price Initiative for Generic Drugs reduces the price by 15–18% of the brand price. Protect your market access by adapting to lower drug prices. Build a roadmap to:
Overcome the challenges of shrinking drug prices to enhance market access.
The growing transparency at CADTH and shrinking hospital budgets are changing the perspective of GPOs. Adapt to GPO’s approach to ensure your access to hospital and community care. Create a roadmap to:
Overcome the challenges of shrinking government budgets when dealing with GPOs.
Adapting a global pricing strategy to Canadian markets continues to be a challenge. Work efficiently with global affiliates and Canadian payers to improve your negotiations. Source insights to:
Enhance your commercialization planning in a global context.
Biosimilar technology has greatly evolved in the past decade and it offers more affordable option to patients. Review pricing trends to optimize your access to market and improve access to treatment. Take away new ideas to:
Review biosimilars trends to provide a greater access to treatments.
The pan-Canadian Pharmaceutical Alliance (pCPA) has established their officce and become a formal process for getting new drugs to the market. Source insights to manage and optimize your submission. Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:
Develop your successful pCPA strategy through this hands-on interactive workshop.
So, you know what pCPA wants and how payers operate. Now what? How can you possibly negotiate value in the face of hard positions?
This is a unique opportunity for participants. The program brings you more than 40 years of combined pharmaceutical experience, blending this with strategies from the world-renowned “Harvard Negotiation Project”, to deliver a truly unique and customized negotiation program for today’s pharmaceutical professionals.